Results 51 to 60 of about 12,125 (226)

Supplementary Material for: Tirofiban for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis: A Systematic Review and Meta-Analysis

, 2022
Introduction: Tirofiban has been used as a rescue when thrombectomy is not successful in endovascular therapy (EVT) for acute ischemic stroke (AIS), but the use of tirofiban after intravenous thrombolysis (IVT) is controversial.
Li X.-Y. (4132864), Liu X.-L. (5051306), Sun B. (3112689), Shi H. (4136188), Hou M.-M. (13902366), He Z.-F. (14308454), Ren G. (4052971)   +6 more
core   +1 more source

Safety of tirofiban in acute ischemic stroke: The SaTIS trial

, 2011
Background and Purpose—Tirofiban is a highly selective, fast-acting nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist with a short half-life time.
Schneider, D., Rother, J., Hamann, G., Witte, O., Junghans, U., Siebler, M., Hennerici, M., Fiebach, J., von Reutern , G., Villringer, A. ; https://orcid.org/, Seitz, R.   +10 more
core   +2 more sources

A functionally distinct HPA‐1a‐specific alloantibody associated with fetal/neonatal alloimmune thrombocytopenia that activates platelets via FcγRIIa

Transfusion, EarlyView.
Abstract Background Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is caused by maternal alloantibodies directed against fetal platelet antigens, most commonly human platelet antigen‐1a (HPA‐1a). These antibodies mediate platelet destruction and can lead to fetal and neonatal thrombocytopenia severe enough to cause life‐threatening organ bleeds ...
Huiying Zhi, Cathy Paddock, Daniel Villalobos‐Garcia, Janita Oosterhoff, Heng Zhang, Gestur Vidarsson, Renren Wen, Jieqing Zhu, Debra Newman, Peter J Newman   +9 more
wiley   +1 more source

Forest plot for endpoints in STEMI patients treated with IC vs. IV administration of tirofiban.

, 2015
(A). Forest plot for TIMI grade 3 flow based on a random-effects model in STEMI patients treated with IC vs. IV administration of tirofiban. (B). Forest plot for TMP grade 3 based on a random-effects model in STEMI patients treated with IC vs.
Peng Liu (120506), Xiuying Tang (5663965), Quanmin Jing (753445), Yingfeng Liu (753446), Runjun Li (753444)   +4 more
core   +1 more source

Clinical safety and possible efficacy of tirofiban in combination with intravenous thrombolysis by recombinant tissue plasminogen activator for early treatment of capsular warning syndrome (CWS)

Frontiers in Neuroscience, 2022
The purpose of this study was to assess the efficacy and safety of the combination of tirofiban with intravenous thrombolysis (IVT) in treating patients with capsular warning syndrome (CWS) who failed to respond to the treatment of intravenous ...
Yunzhu Liu, Shiyong Li, Dongdong Hao, Zhongping Zhang, Yongxin Yi, Jiayang Fang, Weizhi Lin, Min Zhang   +7 more
doaj   +1 more source

Incidence of Periprocedural Myocardial Injury and Infarction After Intravascular Lithotripsy for Calcified Coronary Artery Stenosis

Catheterization and Cardiovascular Interventions, Volume 108, Issue 5, Page 1926-1933, November 1, 2026.
ABSTRACT Background Intravascular lithotripsy (IVL) has emerged as an effective technique for modifying heavily calcified coronary plaques, facilitating optimal stent expansion while minimizing procedural complications. However, data on periprocedural myocardial injury (PMI) and infarction (PPMI) following IVL remain scarce.
Gwaenaelle Aellen, Dorian Garin, Yannick Faucherre, Serban Puricel, Mario Togni, Stéphane Cook   +5 more
wiley   +1 more source

Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia

American Journal of Hematology, Volume 101, Issue 10, Page 2571-2580, October 2026.
ABSTRACT Chronic liver disease (CLD)‐related thrombocytopenia can limit the feasibility of invasive procedures. Recombinant human thrombopoietin (rhTPO) has demonstrated a favorable safety profile without hepatotoxicity. We evaluated the efficacy and safety of rhTPO in patients with CLD‐related thrombocytopenia who were undergoing elective invasive ...
Yifan Han, Ning Lin, Jinghang Xu, Sikui Wang, Jinglan Jin, Jia Shang, Yongning Xin, Youwen Tan, Dazhi Zhang, Jinlin Hou, Ping An, Wen Xie, Yujuan Guan, Qingfang Xiong, Hong Wu, Huiguo Ding, Yu Chen, Rongkuan Li, Zhili Wen, Mingqin Lu, Jinhui Yang, Zhongyin Zhou, Yongjian Zhou, Zujiang Yu, Kecan Lin, Wei Wang, Yan Huang, Yuemin Nan, Xinhua Luo, Rongshu Shi, Yi Kang, Tao Han, Shiyan Chen, Kai Wang, Yunfeng Shan, Jiaping Li, Pingguo Liu, Zheng Lu, Jun Chen, Zhen Liu, Liaoyun Zhang, Li Yang, Jifang Sheng, Zhan Zeng, Yanyan Yu, Xiaoyuan Xu   +45 more
wiley   +1 more source

Tirofiban Blocks Platelet Adhesion to Fibrin with Minimal Perturbation of GpIIb/IIIa Structure

, 2002
SummaryA biophysical approach tested the hypothesis that tirofiban, like eptifibatide, perturbs GpIIb/IIIa structure. Tirofiban bound tightly to platelet GpIIb/IIIa (EC50 ∼ 24 nmol/L) and effectively inhibited platelet aggregation (IC50 ∼ 37 nmol/L) but ...
Roy Hantgan, Chandrasekaran Nagaswami, Mary Stahle, John Weisel, Gray Jerome   +4 more
core   +1 more source

Safety and Efficacy of Ultra‐Early Tirofiban Treatment Following Alteplase in Patients With Noncardioembolic Acute Ischemic Stroke

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Secondary platelet activation peaks ≈2 hours after intravenous thrombolysis with alteplase. This study evaluated the safety and efficacy of ultra‐early tirofiban administration and compared different tirofiban regimens following intravenous ...
Qing Zhao, Yi Yang, Wangsheng Jin, Huaqiao Chi, De Yang, Shengli Chen, Chengchun Liu, Ya Wu, Xiaoshu Li, Zhiqiang Sun, Wenjun Han, Zihao Wang, Rongchang Zhao, Yanjiang Wang, Wei Li, Meng Zhang   +15 more
doaj   +1 more source

Design, Synthesis of 3‐n‐Butylphthalide‐Hydrazine/Hydrazide Derivatives as Potential Anti‐Ischemic Stroke Agents

Chemistry &Biodiversity, Volume 23, Issue 10, October 2026.
A series of 3‐n‐butylphthalide hydrazine and hydrazide hybrids were synthesized. Among them, NBP‐HY exhibited superior antiplatelet activity compared to both NBP and aspirin. In vivo experiments confirmed that NBP‐HY possesses potent antithrombotic and anti‐ischemic stroke efficacy, coupled with moderate metabolic stability, favorable blood–brain ...
Yong Li, Manju Wang, Qing Zhang, Pengfei Zhou, Ya Yang, Lei Tang, Judi Fan, Lingling Fan   +7 more
wiley   +1 more source